Preclinical pharmacokinetics-pharmacodynamics (PK-PD) modeling of TAK-733, an investigational MEK inhibitor

被引：0
|
作者：
Le, K. [1 ]
Chakravarty, A. [2 ]
Walker, R. [3 ]
Izmailova, E. [3 ]
Vincent, P. [4 ]
O'Connell, S. [4 ]
Prakash, S. [1 ]
机构：
[1] Millennium Takeda Oncol Co, Drug Metab & Pharmacokinet, Cambridge, MA USA
[2] Millennium Takeda Oncol Co, Canc Pharmacol, Cambridge, MA USA
[3] Millennium Takeda Oncol Co, Mol Med, Cambridge, MA USA
[4] Takeda San Diego Inc, Discovery Biol, San Diego, CA USA
来源：
EJC SUPPLEMENTS | 2010年 / 8卷 / 07期
关键词：
D O I：
10.1016/S1359-6349(10)72307-7
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：188 / 189
页数：2
相关论文
共 50 条
  • [1] Pharmacokinetics and Pharmacodynamics of TAK-733, an Investigational, Oral MEK Inhibitor, in Patients with Advanced Nonhematologic Malignancies
    Zhou, X.
    Faucette, S.
    Kaun, S.
    Gangolli, E.
    Bozon, V.
    Venkatakrishnan, K.
    EUROPEAN JOURNAL OF CANCER, 2012, 48 : 121 - 122
  • [2] Multiorgan-on-a-chip for cancer drug pharmacokinetics-pharmacodynamics (PK-PD) modeling and simulations
    Abdurehman Eshete Mohammed
    Filiz Kurucaovalı
    Devrim Pesen Okvur
    Journal of Pharmacokinetics and Pharmacodynamics, 2025, 52 (1)
  • [3] Effects of the investigational selective MEK inhibitor TAK-733 against cutaneous and uveal melanoma cell lines
    von Euw, Erika
    Atefi, Mohammad
    Attar, Narsis
    Zachariah, Sybil
    Burgess, Barry L.
    McCannel, Tara
    Lichter, David I.
    Izmailova, Elena
    Ribas, Antoni
    CANCER RESEARCH, 2011, 71
  • [4] Lansoprazole suspension pharmacokinetics-pharmacodynamics (PK-PD) in critically ill pediatric patients.
    DiGiacinto, J
    Graumlich, JF
    Bysani, GK
    Torres, A
    Shushunov, S
    Kastrissios, H
    Scheibel, LW
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2000, 67 (02) : 104 - 104
  • [5] Evaluation of Predictive Biomarkers for the Antineoplastic Effect of TAK-733, a Novel Investigational Allosteric Inhibitor of MEK1/2
    Gangolli, E.
    Blair, D.
    Schu, M.
    Szynal, C.
    Ecsedy, J.
    Hori, A.
    Dorner, A.
    Bolen, J.
    Vincent, P.
    Chakravarty, A.
    EUROPEAN JOURNAL OF CANCER, 2012, 48 : 151 - 151
  • [6] Carbamazepine (CBZ) pharmacokinetics-pharmacodynamics (PK-PD) in genetically epilepsy-prone rats (GEPRs).
    Graumlich, JF
    McLaughlin, RG
    Birkhahn, DK
    Shah, N
    Buck, A
    Jobe, PC
    Dailey, JW
    FASEB JOURNAL, 1999, 13 (05): : A810 - A810
  • [7] A phase I dose-escalation study of TAK-733, an investigational oral MEK inhibitor, in patients with advanced solid tumors
    Alex A. Adjei
    Patricia LoRusso
    Antoni Ribas
    Jeffrey A. Sosman
    Anna Pavlick
    Grace K. Dy
    Xiaofei Zhou
    Esha Gangolli
    Michelle Kneissl
    Stephanie Faucette
    Rachel Neuwirth
    Viviana Bózon
    Investigational New Drugs, 2017, 35 : 47 - 58
  • [8] A phase I dose-escalation study of TAK-733, an investigational oral MEK inhibitor, in patients with advanced solid tumors
    Adjei, Alex A.
    LoRusso, Patricia
    Ribas, Antoni
    Sosman, Jeffrey A.
    Pavlick, Anna
    Dy, Grace K.
    Zhou, Xiaofei
    Gangolli, Esha
    Kneissl, Michelle
    Faucette, Stephanie
    Neuwirth, Rachel
    Bozon, Viviana
    INVESTIGATIONAL NEW DRUGS, 2017, 35 (01) : 47 - 58
  • [9] Discovery of TAK-733, a potent and selective MEK allosteric site inhibitor for the treatment of cancer
    Dong, Qing
    Dougan, Douglas R.
    Gong, Xianchang
    Halkowycz, Petro
    Jin, Bohan
    Kanouni, Toufike
    O'Connell, Shawn M.
    Scorah, Nicholas
    Shi, Lihong
    Wallace, Michael B.
    Zhou, Feng
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2011, 21 (05) : 1315 - 1319
  • [10] Combination treatment with the investigational RAF kinase inhibitor MLN2480 and the investigational MEK kinase inhibitor TAK-733 inhibits the growth of BRAF mutant and RAS mutant preclinical models of melanoma and CRC.
    Cunniff, Elizabeth Grace Carideo
    Zhang, Julie
    Chouitar, Jouhara
    Mettetall, Jerome
    Nakamura, Kazuhide
    Arita, Takeo
    Nakamura, Akito
    Okaniwa, Masanori
    Ishikawa, Tomoyasu
    Yoshida, Sei
    Fabrey, Robyn
    Vincent, Patrick
    Eng, Kurt
    Garcia, Khristofer
    Borelli, Deanna
    Vagrhese, Teena
    Stroud, Steve
    Menon, Saurabh
    Kuranda, Mike
    Galvin, Katherine
    MOLECULAR CANCER THERAPEUTICS, 2013, 12 (11)
12345